肠易激综合征：当前治疗理念的简要综述
Irritable bowel syndrome: a concise review of current treatment concepts.
作者信息
Wall Geoffrey C, Bryant Ginelle A, Bottenberg Michelle M, Maki Erik D, Miesner Andrew R
机构信息
Geoffrey C Wall, Ginelle A Bryant, Michelle M Bottenberg, Erik D Maki, Andrew R Miesner, Department of Pharmacy Practice, Drake University College of Pharmacy, Des Moines, IA 50311, United States.
出版信息
World J Gastroenterol. 2014 Jul 21;20(27):8796-806. doi: 10.3748/wjg.v20.i27.8796.
Abstract
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders causing patients to seek medical treatment. It is relatively resource intensive and the source of significant morbidity. Recent insights into the pathophysiology and treatment of IBS has given clinicians more options than ever to contend with this disorder. The purpose of our paper is to review older, "classic" treatments for IBS as well as newer agents and "alternative" therapies. We discuss the evidence base of these drugs and provide context to help develop appropriate treatment plans for IBS patients.
摘要
肠易激综合征（IBS）是导致患者寻求医疗救治的最常见胃肠道疾病之一。它相对耗费资源，且是严重发病的根源。最近对肠易激综合征病理生理学和治疗的深入了解，为临床医生应对这种疾病提供了比以往更多的选择。我们论文的目的是回顾针对肠易激综合征的较老的“经典”治疗方法以及新药物和“替代”疗法。我们讨论这些药物的证据基础，并提供相关背景信息，以帮助为肠易激综合征患者制定合适的治疗方案。
相似文献
1
Irritable bowel syndrome: a concise review of current treatment concepts.
World J Gastroenterol. 2014 Jul 21;20(27):8796-806. doi: 10.3748/wjg.v20.i27.8796.
2
Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.
World J Gastroenterol. 2014 Mar 14;20(10):2499-514. doi: 10.3748/wjg.v20.i10.2499.
3
Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches.
Handb Exp Pharmacol. 2017;239:75-113. doi: 10.1007/164_2016_102.
4
Irritable bowel syndrome - The role of complementary medicines in treatment.
Aust Fam Physician. 2009 Dec;38(12):966-8.
5
Probiotics and irritable bowel syndrome.
World J Gastroenterol. 2013 Sep 28;19(36):5973-80. doi: 10.3748/wjg.v19.i36.5973.
6
Is irritable bowel syndrome an infectious disease?
World J Gastroenterol. 2016 Jan 28;22(4):1331-4. doi: 10.3748/wjg.v22.i4.1331.
7
Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
World J Gastroenterol. 2015 Mar 14;21(10):3072-84. doi: 10.3748/wjg.v21.i10.3072.
8
Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.
World J Gastroenterol. 2014 Jul 21;20(27):8886-97. doi: 10.3748/wjg.v20.i27.8886.
9
Novel pharmacological therapies for irritable bowel syndrome.
Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):807-15. doi: 10.1586/17474124.2016.1158099. Epub 2016 Mar 18.
10
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
World J Gastroenterol. 2014 Jul 21;20(27):8898-909. doi: 10.3748/wjg.v20.i27.8898.
引用本文的文献
1
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms.
AMB Express. 2024 Dec 24;14(1):141. doi: 10.1186/s13568-024-01809-x.
2
Prevalence and Risk Factors of Irritable Bowel Syndrome Among Adults in Al-Qunfudah Governorate, Saudi Arabia.
Cureus. 2023 Nov 11;15(11):e48639. doi: 10.7759/cureus.48639. eCollection 2023 Nov.
3
Chaihu-Guizhi-Ganjiang Decoction is more efficacious in treating irritable bowel syndrome than Dicetel according to metabolomics analysis.
Chin Med. 2022 Dec 14;17(1):139. doi: 10.1186/s13020-022-00695-4.
4
Pre-Antibiotic Treatment Followed by Prolonged Repeated Faecal Microbiota Transplantation Improves Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome: An Observational Australian Clinical Experience.
Gastroenterol Res Pract. 2022 Oct 13;2022:6083896. doi: 10.1155/2022/6083896. eCollection 2022.
5
A Systematic Review on the Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in Gastrointestinal Motility Disorders: More Control, Less Risk.
Cureus. 2022 Aug 4;14(8):e27691. doi: 10.7759/cureus.27691. eCollection 2022 Aug.
6
Comparison of fluoxetine and duloxetine hydrochloride therapeutic effects on patients with constipation-predominant irritable bowel syndrome.
Gastroenterol Hepatol Bed Bench. 2022 Winter;15(1):45-52.
7
Effect of probiotics and dietary fiber combined with pinaverium bromide on intestinal flora in patients with irritable bowel syndrome.
Am J Transl Res. 2021 Dec 15;13(12):14039-14045. eCollection 2021.
8
Increased colon transit time and faecal load in irritable bowel syndrome.
World J Gastrointest Pharmacol Ther. 2021 Jan 5;12(1):13-20. doi: 10.4292/wjgpt.v12.i1.13.
9
Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial.
Medicine (Baltimore). 2021 Jan 22;100(3):e23887. doi: 10.1097/MD.0000000000023887.
10
Electroacupuncture Improves IBS Visceral Hypersensitivity by Inhibiting the Activation of Astrocytes in the Medial Thalamus and Anterior Cingulate Cortex.
Evid Based Complement Alternat Med. 2020 Jun 12;2020:2562979. doi: 10.1155/2020/2562979. eCollection 2020.
本文引用的文献
1
Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
Am J Gastroenterol. 2013 Sep;108(9):1508-15. doi: 10.1038/ajg.2013.197. Epub 2013 Jul 9.
2
Linaclotide for the treatment of irritable bowel syndrome with constipation: is it time to reshuffle the deck?
Gastroenterology. 2013 Aug;145(2):476-8. doi: 10.1053/j.gastro.2013.06.017. Epub 2013 Jun 20.
3
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi: 10.1016/j.cgh.2013.04.032. Epub 2013 May 2.
4
An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.
Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089. Epub 2013 Feb 6.
5
Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance?
J Clin Gastroenterol. 2013 Mar;47(3):205-11. doi: 10.1097/MCG.0b013e31827559a3.
6
Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
Aliment Pharmacol Ther. 2012 Dec;36(11-12):1084-93. doi: 10.1111/apt.12087. Epub 2012 Oct 16.
7
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725. doi: 10.1038/ajg.2012.255.
8
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Am J Gastroenterol. 2012 Nov;107(11):1702-12. doi: 10.1038/ajg.2012.254.
9
Diagnosis and management of IBS in adults.
Am Fam Physician. 2012 Sep 1;86(5):419-26.
10
Irritable bowel syndrome.
BMJ. 2012 Sep 4;345:e5836. doi: 10.1136/bmj.e5836.
Zotero 插件